Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

• Published in: The New England journal of medicine Vol. 333; no. 20; pp. 1301 - 1308
• Main Authors: Shepherd, James, Cobbe, Stuart M, Ford, Ian, Isles, Christopher G, Lorimer, A. Ross, Macfarlane, Peter W, McKillop, James H, Packard, Christopher J
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 16-11-1995
• Subjects: Biological and medical sciences; Cardiovascular disease; Cholesterol; Drug therapy; General and cellular metabolism. Vitamins; Heart attacks; Medical research; Medical sciences; Pharmacology. Drug treatments; Performance evaluation; Human; Cardiovascular disease; Metabolic diseases; Lipids; Hyperlipoproteinemia; Coronary heart disease; Statistical study; Prevention; Chemotherapy; Hypercholesterolemia; Double blind study; Antilipemic agent
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199511163332001

Earlier trials of lipid-lowering drugs in the primary prevention of coronary heart disease have demonstrated that lowering cholesterol levels in middle-aged men with hypercholesterolemia reduces the incidence of myocardial infarction.
1
–
4
However, these studies, because of their design and low rates of observed events, were unable to show a clear effect of therapy on the risk of death from coronary heart disease or death from any cause. A meta-analysis of the trials provided support for the likelihood that therapy lowered the risk of death from coronary heart disease, but it also aroused concern that the risk of death from noncardiovascular . . .